SEER - Seer, Inc. Stock Price, Fair Value and News

$2.06-0.02 (-0.96%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

SEER Price Action

Last 7 days

3.5%


Last 30 days

-0.9%


Last 90 days

0.5%


Trailing 12 Months

25.3%

SEER RSI Chart

NovDec2025FebMarAprMayJunJulAug0102030405060708090

SEER Valuation

Market Cap

131.3M

Price/Earnings (Trailing)

-1.59

Price/Sales (Trailing)

8.06

EV/EBITDA

-1.16

Price/Free Cashflow

-2.41

SEER Price/Sales (Trailing)

2022202320242025050100150200250300

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SEER Fundamentals

SEER Revenue

Revenue (TTM)

16.3M

Rev. Growth (Yr)

31.87%

Rev. Growth (Qtr)

-3.66%

2021202220232024202505M10M15M

SEER Earnings

Earnings (TTM)

-82.4M

Earnings Growth (Yr)

14.99%

Earnings Growth (Qtr)

2.63%

20212022202320242025-90M-80M-70M-60M-50M-40M-30M

SEER Profitability

Operating Margin

49.94%

EBT Margin

-531.07%

Return on Equity

-28.6%

Return on Assets

-25.56%

Free Cashflow Yield

-41.53%

SEER Investor Care

Diluted EPS (TTM)

-1.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202515.3M16.3M00
202415.7M14.7M14.6M14.2M
202316.2M16.6M16.8M16.7M
20229.9M12.2M14.0M15.5M
20212.1M3.6M5.1M6.6M
2020000656.0K
Get all data in R, Python etc through our Historical Stock Data APIs
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Oregon Health & Science University; The Broad Institute of MIT and Harvard; Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Seer, Inc. Frequently Asked Questions


What is the ticker symbol for Seer, Inc.? What does SEER stand for in stocks?

SEER is the stock ticker symbol of Seer, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Seer, Inc. (SEER)?

As of Thu Aug 14 2025, market cap of Seer, Inc. is 131.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SEER stock?

You can check SEER's fair value in chart for subscribers.

Is Seer, Inc. a good stock to buy?

The fair value guage provides a quick view whether SEER is over valued or under valued. Whether Seer, Inc. is cheap or expensive depends on the assumptions which impact Seer, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SEER.

What is Seer, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Aug 14 2025, SEER's PE ratio (Price to Earnings) is -1.59 and Price to Sales (PS) ratio is 8.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SEER PE ratio will change depending on the future growth rate expectations of investors.